Background: Circulating antipituitary antibodies (APA) are markers of autoimmune hypophysitis, which may cause deficient pituitary function. The prevalence of APA in autoimmune thyroid disorders (AITD) is uncertain.
A UTOIMMUNE THYROID DISEASE (AITD), either
Graves' disease (GD) or chronic autoimmune (Hashimoto's) thyroiditis (HT), is frequently isolated but may be associated with other autoimmune disorders in autoimmune polyglandular syndromes (APS) (1, 2) . According to Betterle et al. (1) , the association of AITD and autoimmune hypophysitis (AH) should identify APS type 3A. Independently of its clinical significance, the real antipituitary antibody (APA) percentage in AITD patients is extremely variable in different series, ranging from 9 -56% in HT and 7-64% in GD (3) (4) (5) (6) (7) . Because data are scant and obtained in small series, the true prevalence and significance of circulating APA remains to be clarified. It is unsettled whether positive tests for circulating APA may herald an impairment of pituitary function. In this regard, it is worth mentioning that APA-positive patients with autoimmune endocrine disorders were reported to have severe GH deficiency (GHD), indeed suggesting a link between serum APA levels and pituitary function (8) .
Aims of the study were 1) to evaluate APA prevalence in a large series of AITD and non-AITD patients and 2) to assess pituitary function in APA-positive patients.
Subjects and Methods Subjects
presence of antithyroid autoantibodies [anti-thyroglobulin (TgAb) and anti-thyroperoxidase (TPOAb)] and hypoechoic pattern at thyroid ultrasonography that can be associated with thyroid dysfunction; for the diagnosis of GD, also the presence of anti-TSH-receptor autoantibodies was required. The non-AITD group consisted of 60 patients with toxic nodular goiter (TNG) (38 untreated and 22 euthyroid on methimazole) and 269 with nontoxic nodular goiter (NTNG) [with (n ϭ 112) or without (n ϭ 157) l-thyroxine TSH-suppressive therapy]. One hundred thirtyfive normal subjects, incorporated in the study at a 1:10 ratio, served as controls (Table 1) .
Study protocol
This study was a health survey in which we analyzed the prevalence of APA in all unselected patients with thyroid diseases coming to our clinic; subsequently, pituitary function assessment was performed in a selected group of the original population. As illustrated in Fig. 1 , after enrollment, patients were submitted to clinical, ultrasonographic, and biochemical assessment. APA-positive subjects were submitted to pituitary function assessment by basal and stimulated pituitary hormone measurement, and by water deprivation test (see below). When there was evidence of pituitary functional defects, magnetic resonance imaging (MRI) of the hypothalamic-pituitary region was performed.
Informed consent was obtained from all subjects. The study was approved by the Institutional Ethics Committee. , and anti-21OH (21-OHAb) and anti-glutamic-acid decarboxylase antibodies (RSR Ltd., Cardiff, Wales, UK) were assayed by commercial kits in all patients and controls. Normal values in our laboratory are as follows: FT 4 , 7.0 -17.0 pg/ml; FT 3 , 2.7-5.7 pg/ml; TSH, 0.4 -3.4 U/ml; TgAb, less than 30 U/ml; TPOAb, less than 10 U/ml; anti-TSH receptor, less than 2 UI/liter; PCAb, less than 20 U/ml; antitransglutaminase, less than 5 U/ml; anti-21OH, less than 2 U/ml; and anti-glutamic-acid decarboxylase, less than 1 U/ml.
Assays and methods
Thyroid ultrasound was performed in all subjects with a real-time instrument with 7.5 MHz linear transducer as previously described (9) . Among 213 patients positive for PCAb, 81 (38%) were submitted to gastroscopy.
APA-positive patients underwent dynamic testing for pituitary function assessment (Fig. 1 ). Eleven patients (9.7%) refused additional examinations. Dynamic tests were performed as previously reported (10 -13) . No patient had been treated with contraceptive pills or transdermal estrogen patches for the last 6 months. The pituitary-adrenal axis was investigated by testing the response of ACTH (Nichols Institute Diagnostics, San Juan Capistrano, CA) and cortisol (Immunotech, Marseille, France) to CRH (100 g as an iv bolus). The pituitary-gonadal axis was investigated with the measurement of basal serum 17␤-estradiol or total testosterone (Access Immunoassay System; Beckman Coulter Inc., Fullerton, CA), and by testing the response of LH and FSH (Access Immunoassay System) to GnRH (100 g as an iv bolus) in premenopausal women. GH secretion was investigated by assessing its response to GHRH (1 g/kg body weight as an iv bolus) plus arginine (diluted 30%, 0.5 mg/kg body weight) and by measuring baseline serum IGF-I (Nichols Advantage human GH and IGF-I assays; Nichols Institute Diagnostics). Serum prolactin (Unicell; Beckman Coulter) was also measured at baseline. Normal values were as follows: early morning cortisol, In normal-weight subjects, diagnosis of mild GHD was defined as a peak GH response to GHRH plus arginine of less than 16.0 g/liter, whereas GHD was severe if peak GH response was less than 9.0 g/liter (11) (12) (13) 16 ). In overweight and obese patients, appropriate cutoff values were applied (17) . In patients positive for APA to neurohypophysis (APA-N) or anterior hypophysis and neurohypophysis (APA-AN) but not in those with only APA to anterior pituitary (APA-A), water balance, urinary specific weight, and plasma and urinary osmolality were assessed. In two patients with laboratory data suggestive for impaired water balance, i.e. hypotonic polyuria (diuresis Ͼ 2.5-3 liters/d and osmolality Ͻ 300 mmol/kg), a water deprivation test, according to Miller et al. was performed (18) . APA-positive patients with abnormal pituitary dynamic tests were submitted to MRI of the hypothalamus-pituitary region with a 1.5-T system (General Electric, Signa Infinity Twinspeed, Milwaukee, WI). MRI protocol included Spin Echo T1 weighted sequences (TR, 500 msec; TE, 15 msec; field of view, 16 cm; matrix, 256 ϫ 256; slice Tk, 3 mm) in the sagittal and coronal planes before and after the administration of contrast media (gadolinium). Evaluation of MRI scans was performed by a single operator (M.C.).
APA were assayed by indirect immunofluorescence (Euroimmun Medizinische Labordiagnostika AG, Lü beck, Germany). In summary, serum (10 l) diluted in PBS-Tween (1 ml), was incubated for 30 min at room temperature on 5-well slides containing cryostat sections of young baboon anterior (for APA-A) and posterior pituitary (for APA-N). APA test was considered positive starting at dilution 1/10. Thereafter, slides were washed with PBS-Tween, and fluorescein-conjugated goat antihuman Ig was added. After a second 30-min incubation, slides were washed again and finally read with a fluorescence microscope.
All sera were evaluated blindly by two investigators (L.M. and L.L.M.). Samples were considered positive when a diffuse immunofluorescence pattern showing an intracytoplasmic staining was observed in the majority of fields; an agreement was always achieved in all cases of conflicting opinion (4%) after additional readings. In each assay, a positive and negative serum control was included (Fig. 2) . Indirect immunofluorescence is a qualitative method; to quantify the degree of positivity, all positive samples were further diluted at 1/30 and 1/90.
Statistical analysis
Data are expressed as mean Ϯ sd for quantitative variables. Comparisons between continuous and categorical parameters (presence/ absence, positive/negative) were performed using ANOVA and 2 test, respectively. P values Ͻ 0.05 were considered as statistically significant.
Results
APA-positive tests were found in 92 of 707 HT patients (13%), 18 of 254 GD patients (7%), three of 329 non-AITD patients (0.9%), and in none of the healthy controls (P Ͻ 0.0001 among the four groups) (Fig. 3) . Pairwise comparison within the AITD group showed that APA tests were more frequently positive in HT than in GD (P ϭ 0.05). Of the 110 AITD APA-positive patients, 49 (5.1%) were positive for APA-A, 11 (1.2%) for APA-N, and 50 (5.2%) for both (APA-AN; data not shown). Thyroid status did not influence APA positivity in either HT or GD patients (data not shown).
Age in APA-positive and APA-negative patients (45 Ϯ 14 vs. 45 Ϯ 15 yr, P ϭ 0.9) did not differ; likewise, age of female and male APA-positive patients was not statistically different, although women tended to be younger (44 Ϯ 14 vs. 51 Ϯ 13 yr, P ϭ 0.09).
The titer of APA differed among the disease categories. In particular, 66 HT and 14 GD patients had 1/10 titer, 18 HT and three GD had 1/30 titer, and eight HT and one GD 1/90 titer (Fig. 4) . The three non-AITD APA-positive patients had 1/10 APA titer (Fig. 4) . No difference was observed between APA-positive and -negative patients regarding the levels of TPOAb (358 Ϯ 378 vs. 352 Ϯ 400 mU/ml, respectively; P ϭ 0.8) and of TgAb (439 Ϯ 637 vs. 378 Ϯ 580 mU/ml, respectively; P ϭ 0.3).
Before APA determination, AITD was associated with other autoimmune disorders in 100 patients (10.4%); associated disorders included atrophic gastritis (n ϭ 43), Addison's disease (n ϭ 26), chronic hypoparathyroidism (n ϭ 3), diabetes mellitus type 1 (n ϭ 13), celiac disease (n ϭ 13), vitiligo (n ϭ 16), premature ovarian failure (n ϭ 10), Sjogren's syndrome (n ϭ 2), in the context of APS type 1 (three patients), 2 (28 patients), or 3 (99 patients). AITD was a priori isolated in 861 of 961 patients (89.6%). Of the 110 APApositive tests, 20 (18.2%) were found in the APS group, whereas 90 (81.8%) belonged to the group of patients with a priori apparently isolated AITD.
After baseline assessment, 102 of 110 APA-positive AITD patients were submitted to evaluation of pituitary function by dynamic testing. GHD was found in 36 patients (35.2%), severe in 18, mild in 18. Median and range of GH after stimulation were 6. (Fig. 4) . No additional anterior pituitary hormone deficiencies were detected. Of two patients with APA-N-positive tests and laboratory parameters suggestive for impaired water balance, one was diagnosed with central diabetes insipidus after water deprivation test. MRI was performed in all patients with GHD. Among the 18 patients with severe GHD, eight had empty sella, two pituitary hyperplasia, and two stalk thickening, whereas six patients showed normal pituitary imaging. Among the 18 patients with mild GHD, nine had stalk thickening (one with an associated nonfunctioning microadenoma), whereas nine patients had no pituitary abnormalities. In summary, 12 patients (66.6%) with severe GHD and nine (50%) with mild GHD had pituitary abnormalities at MRI.
Patients with APA positivity, pituitary impairment, and/or radiological alterations could be classified as APS type 3A (18); accordingly, the overall percentage of APS in our series of 961 AITD patients increased, after searching for APA, from 10.4 to 13.5%.
Discussion
Pituitary autoimmunity represents a relatively recent aspect of endocrine autoimmunity, but several papers have shown the presence of AH (19 -22) , based on the demonstration of APA by different methods (23) (24) (25) . However, in previous studies, APA was detected not only in AH patients (26) but also in normal subjects and in patients with pituitary adenomas (27, 28) , empty sella syndrome (29) , and Sheehan's syndrome (30) . AH has been found in patients with other autoimmune disorders, such as Addison's disease, type 1 diabetes mellitus, and chronic autoimmune hypoparathyroidism (31, 32) .
The nature of autoantigen(s) recognized by APA is a matter of argument; neurone-specific enolase (␣-and ␥-isoforms) (33, 34) , human GH, pituitary gland-specific factor 1a and 2 (35), a 36-kDa pituitary protein (36) , and type 2 iodothyro- nine deiodinase (6) have been proposed as putative candidate antigens, but this remains to be clarified. As illustrated in Table 2 , APA have been looked for in relatively small series of AITD patients (3-7, 8, 24) . Results of different studies have provided a wide variability of APA prevalence in AITD patients, possibly owing to selection of patients, wider study population, or different methods for APA determination (with different sensitivity/specificity and substrates).
To contribute to this issue, we carried out a large morbidity survey in AITD or non-AITD patients, and in control subjects. In keeping with previous studies, we found a high APA frequency (more than 11%) in AITD, particularly in HT. Indeed, APA percentage in HT was almost 2-fold that found in GD (13 vs. ϳ7%). Only three non-AITD patients, and no healthy control, had APA-positive tests. Thus, APA (at low titer) was found only in less than 1% of about 500 subjects who had no signs of organ-specific autoimmunity (non-AITD patients plus controls). An interesting finding of our study is that 90 of the 110 (81.8%) AITD patients who proved to have circulating APA were initially classified as isolated AITD, owing to the absence of other commonly sought organ-specific or non-organ-specific autoantibodies. Thus, according to Betterle et al. (1) , APA can be the only additional autoimmune phenomenon in patients with apparently isolated AITD. As a consequence of APA determination, pituitary function tests, and MRI, in our large series of AITD patients, APS percentage raised from 10.4 to 13.5%.
Whether APA represents an autoimmune marker of pituitary deficiency is a matter of discussion. Low APA titers were associated with a normal pituitary function, whereas patients with high APA titers had severe GHD (8) . Thus, the finding of APA positivity in so-called idiopathic GHD suggests an autoimmune origin of this disorder. In the present study, GHD, as assessed by a GHRH plus arginine stimulation test, was found in 35.2% of APA-positive patients, half of whom had severe GHD. A limitation of our study may be represented by the fact that our GH assay (immunochemiluminescent assay) was different from the one used to define the cutoff for GHD (immunoradiometric assay) (11-13); however, in our laboratory, we compared both assays, obtaining an excellent correlation (r ϭ 0.98). In agreement with De Bellis et al. (8) , GHD was much more common in patients with high APA titers (66.6%) than in those with moderate or low APA titers (52.6 and 27.0%, respectively). In addition, no other pituitary hormone deficiency, with the exception of central diabetes insipidus in one patient positive for APA-AN, was found. A high frequency of abnormalities of pituitary region morphology at MRI was detected in patients with severe (66.6%) and mild GHD (50%), frequently represented by symmetrical pituitary enlargement and pituitary stalk thickening, which are typical of AH. Considering the high number of patients (eight of 36) bearing empty sella in our series, it is tempting to speculate that primary empty sella syndrome might be the endpoint of the chronic inflammatory pituitary process.
AH is the most frequent form of primary hypophysitis; it may involve either the anterior lobe (adenohypophysitis), the posterior lobe (infundibulo-neurohypophysitis), or both (pan-hypophysitis) (26) . Its autoimmune origin is suggested by the bioptic finding of pituitary lymphocytic infiltration (37) . On clinical grounds, AH should be suspected in the presence of pituitary enlargement with symmetrical suprasellar extension, pituitary stalk thickening, or intense homogeneous pituitary enhancement after gadolinium injection on MRI or symptoms/signs of pituitary failure (38, 39 ). An indirect support to AH diagnosis derives from its improvement (associated with reduction of pituitary enlargement) during immunosuppressive therapy (40) . Thus, we can hypothesize that in our APA-positive patients with pituitary impairment and/or radiological abnormalities, AH could be diagnosed.
GHD represents one of the first abnormalities of the pituitary gland function; accordingly, the absence of the other hormonal deficits suggests that AH is likely mild in most cases. However, it is quite possible that a more severe picture of pituitary hormone deficiency may develop in cases of more marked autoimmune inflammation. In this regard, because prospective studies are lacking, periodical evaluation of pituitary function (and APA titers) appears to be indicated, not only in patients with high APA titers but also in those with initially low APA titers.
In conclusion, this large study showed, in agreement with previous smaller studies, that APA is frequently found in patients affected by AITD. APA detection allows us to establish a higher prevalence of APS in AITD patients with apparently no other autoimmune phenomena but thyroid autoantibodies. GHD is common in high-titer APA-positive patients, warranting a periodical evaluation of pituitary function in APA-positive patients.
